1. Home /
  2. Biotechnology

Biotechnology

AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles

AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles

AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

Jitters Not Justified

Jitters Not Justified

Despite steady selling Thursday the markets are not on the verge of disaster -- and thanks to several IPOs, opportunities are here.

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

Novocure Could Climb Even Further; Here's Where to Buy

Novocure Could Climb Even Further; Here's Where to Buy

The oncology company already has risen significantly this year, but its charts indicate the rally could continue.

Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal

Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal

Initial inquiry into deal showed it could remove what might be most significant competitive threat to Illumina.

Biotech, Small Cap Speculation Liven Dull Day in Markets

Biotech, Small Cap Speculation Liven Dull Day in Markets

Takeover action in biotech and speculative interest in small caps kept things interesting during an otherwise sleepy Monday, as everyone awaits Wednesday's Fed decision.

United Natural Foods Is Gathering Ingredients For Opportunity

United Natural Foods Is Gathering Ingredients For Opportunity

Appetite is growing for UNFI as the company is cutting debt and surpassing consensus earnings' estimates.

UniQure Jumps on Report It's Exploring a Possible Sale

UniQure Jumps on Report It's Exploring a Possible Sale

A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.

Savara Shares Slammed on Failed Phase 3 Drug Study

Savara Shares Slammed on Failed Phase 3 Drug Study

Treatment for rare lung disease misses test goals, sending shares into tailspin.